Has Renae Klee received payments from drug or device companies?

Yes. Drug and device makers reported $6,352 in general payments to Renae Klee across 213 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Renae Klee did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Renae Klee come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Renae Klee

Nurse Practitioner · Sacramento, CANPI 1609981125

Payments from drug & device makers

$6,352in general payments, 2019–2025

Across 213 payments — averaging $29.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Johnson & Johnson$2K
Teva Pharmaceuticals USA, Inc.$1K
Alkermes, Inc.$716
Neurocrine Biosciences, Inc.$679
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$638
Otsuka America Pharmaceutical, Inc.$431
plus $939 from 6 others

What the payments were for

Food & beverage$6,15897%
Education$1943%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Johnson & Johnson	39	$1,813
Teva Pharmaceuticals USA, Inc.	33	$1,136
Alkermes, Inc.	25	$716
Neurocrine Biosciences, Inc.	22	$679
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	30	$638
Otsuka America Pharmaceutical, Inc.	25	$431
Indivior Inc.	15	$346
AbbVie	12	$319
E.r. Squibb & Sons, L.L.C.	7	$163
Vanda Pharmaceuticals Inc.	2	$49
Lundbeck LLC	2	$40
Takeda Pharmaceuticals U.S.A., Inc.	1	$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,352 in reported general payments places this provider in the 95th percentile of 6,779 nurse practitioner providers in California.

See all nurse practitioner providers in California →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Invega SustennaPaliperidone Palmitate	45	$151,644
Invega TrinzaPaliperidone Palmitate	14	$139,476
VraylarCariprazine Hcl	38	$33,127
CaplytaLumateperone Tosylate	36	$22,069
LybalviOlanzapine/Samidorphan Malate	13	$19,065
Divalproex Sodium ErDivalproex Sodium	40	$1,218
Quetiapine Fumarate	97	$1,152
Aripiprazole	64	$1,137
Haloperidol	35	$665
Olanzapine	64	$614
Fluvoxamine Maleate	12	$382
Benztropine Mesylate	72	$320
Perphenazine	35	$288
Clozapine	14	$261
Gabapentin	40	$238

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza	$1,813	$291,12059 claims
AbbVieVraylar	$319	$33,12738 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta	$638	$22,06936 claims
Alkermes, Inc.Lybalvi	$716	$19,06513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,779 nurse practitioner providers in California.

Other nurse practitioner in Sacramento

Rhonda HewittStanford$917K
Linda TrinhIrvine$899K
Denise SinagaNorthridge$728K
Debbie TaySanta Monica$642K
Joe GorelickCampbell$638K
Lynsey LakinArcadia$540K
Kelly ChoiRancho Cucamonga$483K
Hamta ZareStanford$428K
Shawna ChrismanRoseville$425K
Angelina CollinsSan Diego$356K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →